Cantor Fitzgerald raised the firm’s price target on Elevance Health to $600 from $580 and keeps an Overweight rating on the shares after the company reported Q1 EPS that beat consensus, telling investors that the firm continues to view Elevance as a 2024 top pick and believes it is positioned to outperform for the remainder of the year. Takeaways that leave the firm “incrementally positive for the remainder of 2024” include what it calls a “conservative reserves boost vs. peers,” more front-end loaded rate renewals, an EPS guidance raise, recent deal synergy and a recovery from the Change outage faster than peers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Options Volatility and Implied Earnings Moves Today, April 18, 2024
- Elevance Health, Inc. (ELV) Q1 Earnings Cheat Sheet
- Centene rises, Molina slides following Floridaâs managed Medicaid awards
- Elevance Health,CD&R in primary care delivery pact, terms undisclosed
- Options Volatility and Implied Earnings Moves This Week, April 15 – April 19, 2024